Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TRPM5 | Q9NZQ8 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675819 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SIGMAR1DGAT2 | |
| SCHEMBL5675747 | 0.84 | ALDH1A1 (0.49) | SLC9A1LMNAALDH1A1NAMPTTP53 | |
| SCHEMBL5752830 | 0.81 | SLC9A1 (0.58) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL1224732 | 0.81 | ALDH1A1 (0.67) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL30715031 | 0.81 | SLC9A1 (0.58) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL1224730 | 0.81 | ALDH1A1 (0.67) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL5752833 | 0.81 | SLC9A1 (0.58) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL29302528 | 0.81 | SLC9A1 (0.58) | SLC9A1LMNATRPM5ALDH1A1HTT | |
| SCHEMBL20380102 | 0.77 | ALDH1A1 (0.52) | LMNAALDH1A1HTTNAMPTSIGMAR1 | |
| SCHEMBL326946 | 0.76 | SLC9A1 (0.49) | SLC9A1ALDH1A1TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | SLC9A1 403/4885LMNA 1089/4885TRPM5 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.